.png)
Oncology Updates - Key Oncology News
- Oncofocus Team
- 15 hours ago
- 2 min read
March 1st Week, 2026
Regulatory Events
🎯 The European Commission approved Incyte’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal. (Ref 1)
❓ How do the outcomes of this regimen compare against the current SOC?
🎯 The US FDA approved Johnson & Johnson Innovative Medicine’s teclistamab (BCMA-directed CD3 T-cell engager) + daratumumab and hyaluronidase-fihj for the treatment of adults with R/R multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. (Ref 2)
❓ What are the clinical outcomes that support this approval?
🎯 The US FDA accepted Takeda and Protagonist Therapeutics’ NDA and granted Priority Review for rusfertide (hepcidin mimetic peptide therapeutic) for the treatment of adults with polycythemia vera (PV). (Ref 3)
❓ Which are the other key promising assets in the PV pipeline landscape?
🎯 The US FDA granted tentative approval for Lantheus’ abbreviated NDA for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA which is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (Ref 4)
❓ What are the key pros and cons of radiopharmaceuticals in this indication?
🎯 The US FDA granted premarket approval to Perimeter Medical Imaging AI’s Claire (AI-enabled imaging device) for intraoperative breast cancer margin assessment. (Ref 5)
❓ Who are the other key players in the AI imaging device industry?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments